<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bakogeorgos, M.</style></author><author><style face="normal" font="default" size="100%">Mountzios, G.</style></author><author><style face="normal" font="default" size="100%">Bournakis, E.</style></author><author><style face="normal" font="default" size="100%">Economopoulou, P.</style></author><author><style face="normal" font="default" size="100%">Kotsantis, G.</style></author><author><style face="normal" font="default" size="100%">Fytrakis, N.</style></author><author><style face="normal" font="default" size="100%">Kouvatseas, G.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author><author><style face="normal" font="default" size="100%">Kentepozidis, N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Geriatric Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adherence</style></keyword><keyword><style  face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Efficacy</style></keyword><keyword><style  face="normal" font="default" size="100%">Elderly patients</style></keyword><keyword><style  face="normal" font="default" size="100%">NSCLC</style></keyword><keyword><style  face="normal" font="default" size="100%">Tolerance</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925183052&amp;doi=10.1016%2fj.jgo.2014.11.001&amp;partnerID=40&amp;md5=ef3e81d91bd89907be3908e5c593a183</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">111 - 118</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: Elderly patients with advanced non-small cell lung cancer (NSCLC) are thought to receive suboptimal treatment mainly due to concerns for poor compliance and/or excessive toxicity. Patients and Methods: Using the age of 70. years as the pre-defined cut-off, we compared elderly patients with advanced NSCLC suitable for first line chemotherapy with their younger counterparts in terms of: i) diagnosis and disease characteristics ii) adherence to treatment schedule, including dose intensity (DI), and relative dose intensity (RDI), iii) toxicity, tolerance, and efficacy outcomes. Results: Among 292 eligible patients, data were available for 245, of whom 107 (43.7%) belonged to the elderly group. This group was more likely to present with co-morbidities, non-smoking current status and diagnosis based on cytology alone. As compared to the non-elderly, elderly patients were more likely to receive single-agent therapy (8.0% vs. 29.2% respectively, p&lt;. 0.001) and less likely to receive platinum-based chemotherapy (80.3% vs. 57.9%, p&lt;. 0.001). Elderly patients also received docetaxel (24.3% vs. 40.4%), and bevacizumab (7.5% vs. 21.3%) significantly less often and received oral vinorelbine (24.3% vs. 11.8%) more frequently. Non-elderly patients were more likely to receive any of the cytotoxic drugs with RDI. &gt;. 0.8 (49.6% vs. 33.0%, p=. 0.012) and RDI. &gt;. 0.9 (29.6% vs. 16%, p=. 0.015). Substantial toxicity, as well as median overall survival did not differ significantly between the two groups. Conclusions: Only one third of the elderly patients received at least 80% of the scheduled treatment intensity. Nearly half received diagnosis based on cytology alone, which may deprive them from new, histology-driven, therapeutic approaches. © 2014 Elsevier Inc.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><notes><style face="normal" font="default" size="100%">Cited By :4Export Date: 21 February 2017</style></notes></record></records></xml>